Annotated record of the detailed examination of Mn deposits from DSDP Site 32, Leg 5 (Cores 5-32-13, 5-32-14)

Site 32 was proposed by the Pacific Advisory Panel at a location over a strong positive magnetic anomaly (Number 13 on the Pittman-Heirtzler scale, 38 million years) where samples of the basement and the basal sediment would be of value in testing hypotheses for origin of the linear magnetic anomalies from this part of the Pacific. Comparison of this site, south of the Pioneer Fracture Zone, with later sites north of the Fracture Zone would be the basis for evaluating the discontinuity formed by the Pioneer.

Annotated record of the detailed examination of Mn deposits from DSDP Site 38, Leg 5 (Cores 5-38-6)

The nonfossiliferous nature of most of the thin sediment sequence at Site 37 had provided little biostratigraphic information for the northern end of the proposed section of sites along 140°W longitude. In an attempt to provide a biostratigraphically more meaningful hole as the high latitude terminus of the meridional section, an additional site (Site 38) was drilled between the Mendocino and Pioneer Fracture Zones.

Strontium isotope and rare earth element geochemistry of basalts from DSDP Leg 37

87Sr/S6Sr ratios have been determined on eleven whole rock basalt samples from DSDP Leg 37. The 87Sr/S6Sr ratios range from 0.70305 +/- 4 to 0.70451 +/- 4 due to alteration and contamination with seawater Sr. Leaching with 5% HF has only a small effect on the 87Sr/86Sr of the samples. However, treatment with 6M HCl in acid digestion bombs at 130°C removes the contaminant more effectively. Altered plagioclase and olivine are dissolved during this process. The mean 87Sr/86Sr of four HCl-treated samples from hole 332A is 0.70299 and that for five samples from hole 332B is 0.70297. The 87Sr/86Sr ratios of treated samples from holes 333A and 335 are 0.70304 +/- 4 and 0.70316 +/- 4, respectively. These 87Sr/86Sr ratios are within the range observed for other basalts elsewhere along the Mid-Atlantic Ridge in the North Atlantic. REE distribution patterns have been determined for four samples, three from hole 332B and one from hole 335. CeN/YbN ratios range from 0.58 to 1.30 and do not correlate with 87Sr/86Sr ratios. The source regions of these basalts appear to have been variable in REE abundances.

Radiative rates for E1, E2, M1, and M2 transitions in F-like ions with 37≤Z≤53

Calculations of energy levels, radiative rates and lifetimes are reported for 17 F-like ions with 37≤Z≤53. For brevity, results are only presented among the lowest 113 levels of the 2s²2p⁵, 2s2p⁶, 2s²2p⁴3ℓ, 2s2p⁵3ℓ, and 2p⁶3ℓ configurations, although the calculations have been performed for up to 501 levels in each ion. The general-purpose relativistic atomic structure package (grasp) has been adopted for the calculations, and radiative rates (along with oscillator strengths and line strengths) are listed for all E1, E2, M1, and M2 transitions of the ions. Comparisons are made with earlier available experimental and theoretical energies, although these are limited to only a few levels for most ions. Therefore for additional accuracy assessments, particularly for energy levels, analogous calculations have been performed with the Flexible Atomic Code (fac), for up to 72 259 levels. Limited previous results are available for radiative rates for comparison purposes, and no large discrepancy is observed for any transition and/or ion.

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

BACKGROUND: Prostate cancer might have high radiation-fraction sensitivity that would give a therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of the efficacy and side-effects of a randomised trial comparing conventional and hypofractionated radiotherapy after 5 years follow-up.

METHODS: CHHiP is a randomised, phase 3, non-inferiority trial that recruited men with localised prostate cancer (pT1b-T3aN0M0). Patients were randomly assigned (1:1:1) to conventional (74 Gy delivered in 37 fractions over 7·4 weeks) or one of two hypofractionated schedules (60 Gy in 20 fractions over 4 weeks or 57 Gy in 19 fractions over 3·8 weeks) all delivered with intensity-modulated techniques. Most patients were given radiotherapy with 3-6 months of neoadjuvant and concurrent androgen suppression. Randomisation was by computer-generated random permuted blocks, stratified by National Comprehensive Cancer Network (NCCN) risk group and radiotherapy treatment centre, and treatment allocation was not masked. The primary endpoint was time to biochemical or clinical failure; the critical hazard ratio (HR) for non-inferiority was 1·208. Analysis was by intention to treat. Long-term follow-up continues. The CHHiP trial is registered as an International Standard Randomised Controlled Trial, number ISRCTN97182923.

FINDINGS: Between Oct 18, 2002, and June 17, 2011, 3216 men were enrolled from 71 centres and randomly assigned (74 Gy group, 1065 patients; 60 Gy group, 1074 patients; 57 Gy group, 1077 patients). Median follow-up was 62·4 months (IQR 53·9-77·0). The proportion of patients who were biochemical or clinical failure free at 5 years was 88·3% (95% CI 86·0-90·2) in the 74 Gy group, 90·6% (88·5-92·3) in the 60 Gy group, and 85·9% (83·4-88·0) in the 57 Gy group. 60 Gy was non-inferior to 74 Gy (HR 0·84 [90% CI 0·68-1·03], pNI=0·0018) but non-inferiority could not be claimed for 57 Gy compared with 74 Gy (HR 1·20 [0·99-1·46], pNI=0·48). Long-term side-effects were similar in the hypofractionated groups compared with the conventional group. There were no significant differences in either the proportion or cumulative incidence of side-effects 5 years after treatment using three clinician-reported as well as patient-reported outcome measures. The estimated cumulative 5 year incidence of Radiation Therapy Oncology Group (RTOG) grade 2 or worse bowel and bladder adverse events was 13·7% (111 events) and 9·1% (66 events) in the 74 Gy group, 11·9% (105 events) and 11·7% (88 events) in the 60 Gy group, 11·3% (95 events) and 6·6% (57 events) in the 57 Gy group, respectively. No treatment-related deaths were reported.

INTERPRETATION: Hypofractionated radiotherapy using 60 Gy in 20 fractions is non-inferior to conventional fractionation using 74 Gy in 37 fractions and is recommended as a new standard of care for external-beam radiotherapy of localised prostate cancer.

FUNDING: Cancer Research UK, Department of Health, and the National Institute for Health Research Cancer Research Network.